{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 41,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide outlines a multi-cohort study design for NVL-520, distinguishing between registrational cohorts and an exploratory cohort.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/37",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.06,
        "y": 0.48
      },
      "kind": "list",
      "text": "Enrollment planned across North America, Europe, Asia and Australia. All patients receive NVL-520 at 100 mg QD. Primary Objective: ORR by blinded, independent central review. Secondary Objectives: Additional efficacy measures.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f1f2ddd-7cd2-4c0d-8d24-6f25e0a7dc5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "ARROS-1 for TKI-naïve and TKI pre-treated ROS1+ NSCLC (N ≈ 225). Ongoing global open-label, multi-cohort Phase 2 with registrational intent.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "736bcd72-895b-440b-8351-bb8a81e83dc6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.55,
        "x": 0.38,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "1L, 1st line; 2L, 2nd line; CBR, clinical benefit rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival; PK, pharmacokinetics; PRO, patient reported outcomes; QD, once daily; TKI, tyrosine kinase inhibitor; TTR, time to response.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfe5f8c0-eba0-4695-b460-ee934e80e0b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.38,
        "y": 0.35
      },
      "kind": "table",
      "text": "ARROS-1 Phase 2 Cohort breakdown by tumor type, treatment status, and prior therapy.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54c93c81-7d5f-4541-b3e4-c6c91bc7fa94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "title",
      "text": "Ongoing ARROS-1 Phase 2 supports goal of moving up the treatment paradigm",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5798d0bb-b443-4cf8-a991-a040782e2a66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "Clinical Development Strategy for ROS1+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b98f340-f876-4e2a-a9b9-8b4dd030db5e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}